234 related articles for article (PubMed ID: 33906574)
1. Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implications.
Gonzales F; Barthélémy A; Peyrouze P; Fenwarth L; Preudhomme C; Duployez N; Cheok MH
Expert Opin Ther Targets; 2021 Apr; 25(4):299-309. PubMed ID: 33906574
[No Abstract] [Full Text] [Related]
2. RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1.
Mill CP; Fiskus W; DiNardo CD; Qian Y; Raina K; Rajapakshe K; Perera D; Coarfa C; Kadia TM; Khoury JD; Saenz DT; Saenz DN; Illendula A; Takahashi K; Kornblau SM; Green MR; Futreal AP; Bushweller JH; Crews CM; Bhalla KN
Blood; 2019 Jul; 134(1):59-73. PubMed ID: 31023702
[TBL] [Abstract][Full Text] [Related]
3. Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.
Metzeler KH; Bloomfield CD
Adv Exp Med Biol; 2017; 962():175-199. PubMed ID: 28299658
[TBL] [Abstract][Full Text] [Related]
4. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
[TBL] [Abstract][Full Text] [Related]
5. Autonomous feedback loop of RUNX1-p53-CBFB in acute myeloid leukemia cells.
Morita K; Noura M; Tokushige C; Maeda S; Kiyose H; Kashiwazaki G; Taniguchi J; Bando T; Yoshida K; Ozaki T; Matsuo H; Ogawa S; Liu PP; Nakahata T; Sugiyama H; Adachi S; Kamikubo Y
Sci Rep; 2017 Nov; 7(1):16604. PubMed ID: 29192243
[TBL] [Abstract][Full Text] [Related]
6. RUNX1 and CBFβ Mutations and Activities of Their Wild-Type Alleles in AML.
Hyde RK; Liu P; Friedman AD
Adv Exp Med Biol; 2017; 962():265-282. PubMed ID: 28299663
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia.
Khan M; Cortes J; Kadia T; Naqvi K; Brandt M; Pierce S; Patel KP; Borthakur G; Ravandi F; Konopleva M; Kornblau S; Kantarjian H; Bhalla K; DiNardo CD
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28933735
[TBL] [Abstract][Full Text] [Related]
8. Identification of Key Genes and Pathways Associated with RUNX1 Mutations in Acute Myeloid Leukemia Using Bioinformatics Analysis.
Zhu F; Huang R; Li J; Liao X; Huang Y; Lai Y
Med Sci Monit; 2018 Oct; 24():7100-7108. PubMed ID: 30289875
[TBL] [Abstract][Full Text] [Related]
9. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
Mendler JH; Maharry K; Radmacher MD; Mrózek K; Becker H; Metzeler KH; Schwind S; Whitman SP; Khalife J; Kohlschmidt J; Nicolet D; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2012 Sep; 30(25):3109-18. PubMed ID: 22753902
[TBL] [Abstract][Full Text] [Related]
10. High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML.
Simon L; Spinella JF; Yao CY; Lavallée VP; Boivin I; Boucher G; Audemard E; Bordeleau ME; Lemieux S; Hébert J; Sauvageau G
Blood; 2020 May; 135(21):1882-1886. PubMed ID: 32315381
[TBL] [Abstract][Full Text] [Related]
11. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling of minimally differentiated acute myeloid leukemia: M0 is a distinct entity subdivided by RUNX1 mutation status.
Silva FP; Swagemakers SM; Erpelinck-Verschueren C; Wouters BJ; Delwel R; Vrieling H; van der Spek P; Valk PJ; Giphart-Gassler M
Blood; 2009 Oct; 114(14):3001-7. PubMed ID: 19666867
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of RUNX1 Mutations in AML: A Meta-Analysis.
Jalili M; Yaghmaie M; Ahmadvand M; Alimoghaddam K; Mousavi SA; Vaezi M; Ghavamzadeh A
Asian Pac J Cancer Prev; 2018 Feb; 19(2):325-329. PubMed ID: 29479958
[TBL] [Abstract][Full Text] [Related]
14. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
Mill CP; Fiskus W; DiNardo CD; Birdwell C; Davis JA; Kadia TM; Takahashi K; Short N; Daver N; Ohanian M; Borthakur G; Kornblau SM; Green MR; Qi Y; Su X; Khoury JD; Bhalla KN
Blood; 2022 Feb; 139(6):907-921. PubMed ID: 34601571
[TBL] [Abstract][Full Text] [Related]
15. Chemogenomic Landscape of
Simon L; Lavallée VP; Bordeleau ME; Krosl J; Baccelli I; Boucher G; Lehnertz B; Chagraoui J; MacRae T; Ruel R; Chantigny Y; Lemieux S; Marinier A; Hébert J; Sauvageau G
Clin Cancer Res; 2017 Nov; 23(22):6969-6981. PubMed ID: 28855357
[No Abstract] [Full Text] [Related]
16. Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia.
Bluteau D; Gilles L; Hilpert M; Antony-Debré I; James C; Debili N; Camara-Clayette V; Wagner-Ballon O; Cordette-Lagarde V; Robert T; Ripoche H; Gonin P; Swierczek S; Prchal J; Vainchenker W; Favier R; Raslova H
Blood; 2011 Dec; 118(24):6310-20. PubMed ID: 21725049
[TBL] [Abstract][Full Text] [Related]
17. Core binding factor genes and human leukemia.
Hart SM; Foroni L
Haematologica; 2002 Dec; 87(12):1307-23. PubMed ID: 12495904
[TBL] [Abstract][Full Text] [Related]
18. An Old Dog Has a New Trick: Somatic Exonic Deletions in RUNX1 Are Frequent in AML.
Chakraborty J; Stengel KR
Clin Cancer Res; 2023 Aug; 29(15):2742-2744. PubMed ID: 37289016
[TBL] [Abstract][Full Text] [Related]
19. Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.
Engel ME; Hiebert SW
Cancer Treat Res; 2010; 145():127-47. PubMed ID: 20306249
[TBL] [Abstract][Full Text] [Related]
20.
Olofsen PA; Touw IP
Mol Cells; 2020 Feb; 43(2):139-144. PubMed ID: 32041395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
